EyeCRO Shows 20/20 Vision

Let’s face it, choosing the wrong contract researcher is short-sighted. Testing the preclinical efficacy and pharmacokinetics of polymer based drug depots for the retina takes serious scientific chops, and a level of expertise that is hard to find. How many researchers and formulation experts can you name that work down to the 100 nm range in nanoparticle production? There just plain aren’t that many out there. And when you narrow that search down to those that have an ophthalmic specialty, the field of view becomes vanishingly small. And in that very small, very hard-to-find group of top-notch specialists, you have to make a choice. You have to look closely at your options. Things to look for? How about treatments that continue to deliver way past a window of a few days or weeks, long term delivery curves, out to six months? How about singular expertise in the use of FDA approved polymers for vitreous depots? And I think that microparticles designed to stay in the vitreous and release the drug plus nanoparticles designed to enter cells directly and release the drug intracellularly are key indicators that you’re dealing with the cutting edge of the leading experts in their field. Basically, there is only one contract researcher out there that has the grasp of technologies from laser to fluorescent micro- and nanoparticles with sizes of 100 to 300 nm, 5um and 30um, has the relationships with university labs to keep costs down, and the history of coming in on time and under budget. EyeCRO is clearly in focus, and the search is over.